pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
JOHNSON & JOHNSON ($JNJ) · news · pharmadog
← back to JOHNSON & JOHNSON
News mentioning $JNJ
106
stories
Jul 15, 26
Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain
biospace
Jul 15, 26
J&J restructures pharma manufacturing footprint at cost of up to $750M
endpoints
Jul 15, 26
STAT+: Celcuity’s breast cancer drug approved, its first
stat
Jul 15, 26
J&J touts Icotyde prescriptions, but not sales, in first full quarter
endpoints
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
Jul 8, 26
Another big premium hike on the horizon
stat
Jul 7, 26
Oberland pours up to $400M into MeiraGTx eye gene therapies
biopharma dive
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
Jun 18, 26
STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more
stat
Jun 16, 26
Neumora depression drug fails; EnGene to cut 50% of staff
biopharma dive
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
Jun 12, 26
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
biopharma dive
Jun 11, 26
STAT+: An obesity drug deep-dive, and peptides move mainstream
stat
Jun 11, 26
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
biopharma dive
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Jun 10, 26
Parabilis sets a record with a $670M biotech IPO
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 8, 26
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
biopharma dive
Jun 8, 26
J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
endpoints
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 4, 26
Parabilis Medicines charts $413M IPO to back peptide pipeline
endpoints
Jun 3, 26
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
biopharma dive
Jun 1, 26
#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
endpoints
Jun 1, 26
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
biopharma dive
May 13, 26
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
biopharma dive
May 11, 26
The capacity crunch in biopharma is a location problem
biopharma dive
May 8, 26
Lilly, Gilead lead pharma’s M&A boom
biopharma dive
← prev
page 3 of 4
next →
